Accessibility Menu

Yarrow Bioscience(NASDAQ) YARW

Market Cap$88.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-96%
1 Year+265%
1 Month-6%
$32.96
-10.92%
-4.04Today
Yarrow Bioscience last closing stock price
MetricPriceDate
Last closeUSD 32.962026-08-31
Yarrow Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.56%USD 39.502026-08-24
1 month-5.88%USD 35.022026-07-31
3 month+72.84%USD 19.072026-06-02
Year to date+101.41%USD 16.362025-12-31
1 year+264.55%USD 9.042025-08-29
3 year-73.08%USD 122.432023-09-01
5 year-96.16%USD 858.142021-09-01
Since inception-99.57%USD 7,636.972020-03-10

Yarrow Bioscience Financials at a Glance

Market Cap

$88.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$482.00K

Net Income (TTM)

-$18.71M

EPS (TTM)

-$23.46

P/E Ratio

-1.41

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$32.96

Volume

83,097.426

Open

$38.49

Previous Close

$32.96

Daily Range

$31.30 - $38.49

52-Week Range

$7.91 - $44.28

Estimated Earnings Date

Nov 5, 2026

YARW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yarrow Bioscience

Yarrow Bioscience Inc is a clinical-stage biotechnology company dedicated to developing innovative therapies for autoimmune thyroid diseases. The company's lead product candidate, YB-101, aims to be a first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody, targeting conditions such as Graves' disease and thyroid eye disease.

Products and Services
  • YB-101: A monoclonal antibody targeting TSHR for autoimmune thyroid diseases
  • Research and development focused on transformative therapies
  • Potential for first-in-class treatment options in the biotechnology sector
Growth Outlook
  • Significant market potential in autoimmune thyroid disease treatments
  • Strong pipeline with ongoing clinical trials for YB-101
  • Increasing demand for innovative therapies in the healthcare sector
Financial Highlights
  • Q2 2026 revenue of $97,000, up from $86,000 in Q1 2026
  • Cash and cash equivalents of $22.9 million as of June 30, 2026
  • Gross profit margin of 93.8% in Q2 2026, indicating strong product potential
Yarrow Bioscience Inc is positioned in a promising sector with a focus on addressing unmet medical needs. The company's lead product, YB-101, has the potential to disrupt existing treatment paradigms for autoimmune thyroid diseases. Recent financial data indicates a steady increase in revenue, reflecting growing interest and potential market traction. The strong cash position provides a solid foundation for continued research and development efforts. With a robust pipeline and a commitment to innovation, Yarrow Bioscience Inc represents an intriguing opportunity in the biotechnology landscape.
AI Generated • Aug 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Rebecca Velez Frey, PharmD

Website

www.yarrowbioscience.com

Headquarters

New Haven, CT 06513, US

YARW Financials

Key Financial Metrics (TTM)

Gross Margin

97.51%

Operating Margin

-4134.65%

Net Income Margin

-3881.54%

Return on Equity

-70.23%

Return on Capital

-107.15%

Return on Assets

-79.26%

Earnings Yield

-70.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$88.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.67M

Volume

83.10K

Avg. Volume

26.88K

Financials (TTM)

Gross Profit

$470.00K

Operating Income

-$19.93M

EBITDA

-$18.85M

Operating Cash Flow

-$16.93M

Capital Expenditure

$0.00

Free Cash Flow

-$16.93M

Cash & ST Invst.

$22.93M

Total Debt

$0.00

Yarrow Bioscience Performance Analysis

Yarrow Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 477,000-48.8%
20232023-12-31USD 424,000-11.1%
20242024-12-31USD 501,00018.2%
20252025-12-31USD 570,00013.8%
Yarrow Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30144.9%
Q42025-12-31-23.1%
Q12026-03-31-33.8%
Q22026-06-3012.8%
Yarrow Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.34-99.1%
20232023-12-31USD -138.481121.2%
20242024-12-31USD -46.77-66.2%
20252025-12-31USD -30.96-33.8%
Yarrow Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-26.3%
Q42025-12-3114.6%
Q12026-03-3142.3%
Q22026-06-3016.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$97.00K

+40.6%

Gross Profit

$91.00K

+31.9%

Gross Margin

93.81%

N/A

Market Cap

$88.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.80M

N/A

Employees

10

N/A

Net Income

-$3.01M

+47.7%

EBITDA

-$2.90M

+49.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$22.93M

-42.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-79.26%

N/A

Return on Invested Capital

-90.33%

N/A

Free Cash Flow

-$1.99M

+81.6%

Operating Cash Flow

-$1.99M

+81.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KTTAPasithea Therapeutics Corp.
$0.57+2.50%
KALAKALA BIO, Inc.
$0.67-2.52%
QNRXQuoin Pharmaceuticals, Ltd.
$6.22+1.63%
BCLIBrainstorm Cell Therapeutics Inc.
$1.07-4.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%
INTCIntel
$89.51+0.00%

Questions About YARW

What is the current price of Yarrow Bioscience?

Yarrow Bioscience is trading at $32.96 per share.

What is the 52-week range for Yarrow Bioscience?

Over the past 52 weeks, Yarrow Bioscience has traded between $7.91 and $44.28.

How much debt does Yarrow Bioscience have?

As of the most recent reporting period, Yarrow Bioscience reported total debt of $0.00.

How much cash does Yarrow Bioscience have on hand?

Yarrow Bioscience reported $22.93M in cash and cash equivalents in its most recent financial results.

What is Yarrow Bioscience’s dividend yield?

Yarrow Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services